Effect of combined praziquantel and recombinant glutathione S-transferase on resistance to reinfection in murine Schistosomiasis mansoni

被引:6
作者
Botros, SS
Makary, EA
Ahmed, KM
Ibrahim, AM
Nashed, NN
El-Nahal, HMS
Doughty, BL
Hassanein, HI
机构
[1] Theodor Bilharz Inst, Dept Pharmacol, Cairo 12411, Egypt
[2] Theodor Bilharz Inst, Dept Parasitol, Cairo 12411, Egypt
[3] Theodor Bilharz Inst, Dept Immunol, Cairo 12411, Egypt
[4] Ain Shams Univ, Fac Sci, Cairo, Egypt
[5] Univ Texas, Galveston, TX 77555 USA
来源
INTERNATIONAL JOURNAL OF IMMUNOPHARMACOLOGY | 2000年 / 22卷 / 11期
关键词
praziquantel; glutathione S-transferase; murine Schistosomiasis mansoni;
D O I
10.1016/S0192-0561(00)00062-X
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
This study was undertaken to evaluate the effect of recombinant Schistosoma mansoni-26 Glutathione S-transferase (rSm 26 GST) or soluble egg antigen (SEA) alone and in addition to praziquantel (PZQ) on the state of resistance to S, mansoni reinfection. The associated changes in the immune responses were evaluated. The experimental group of mice were injected intravenously before S. mansoni infection (80 cercariae/mouse) either with rSm26 GST (1 mug x 4) or SEA (10 mug x 4) in addition to PZQ (2 x 500 mg/kg) administered 6 weeks post-infection. Seven control groups were used, three of them were the infected (80 cercariae/mouse), the challenged (240 cercariae/mouse) and the infected challenged controls (80+240 cercariae/mouse). The rest of the four groups were the treated controls receiving: the GST-Lyzate, rSmGST, SEA and PZQ in the same doses and at the same timings. Challenge infection was conducted for all the groups 8 weeks post-infection. Animals were sacrificed 3 weeks post-challenge. After sacrifice animals were perfused and percentage resistance to reinfection was calculated. Immune responses were assessed by the measurement of hepatic granuloma diameter, intralesional T-cell phenotypes and serum immunoglobulin isotypes. The highest percentage of resistance to reinfection was observed in rGST-treated group while the lowest percentage of resistance was detected in PZQ-treated group. Whereas in mice receiving combined rGST or SEA and PZQ, percentage resistance to reinfection was significantly higher than that in PZQ treated mice. The remarkable reduction in granuloma diameter in rGST-treated group with or without PZQ was associated with decrease in the intralesional L3T4+ and increase in Lyt(2)(+) T-cell phenotypes. However, no special relationship was observed between the percentage of resistance and the changes in granuloma diameter or intralesional T-cell phenotypes. The increase in percentage resistance to reinfection was found accompanied by increased anti SWAP IgE. Combined rGST and PZQ provided the complementary goals of improved state of resistance to reinfection 'which was compromized after cure with PZQ' and the maximal reduction in granuloma diameter. (C) 2000 Published by Elsevier Science Ltd on behalf of International Society for Immunopharmacology. All rights reserved.
引用
收藏
页码:979 / 988
页数:10
相关论文
共 33 条
[1]   PRAZIQUANTEL [J].
ANDREWS, P ;
THOMAS, H ;
POHLKE, R ;
SEUBERT, J .
MEDICINAL RESEARCH REVIEWS, 1983, 3 (02) :147-200
[2]  
Barakat R, 1995, TROP GEOGR MED, V47, P271
[4]   DELAYED HYPERSENSITIVITY-TYPE GRANULOMA FORMATION AND DERMAL REACTION INDUCED AND ELICITED BY A SOLUBLE FACTOR ISOLATED FROM SCHISTOSOMA MANSONI EGGS [J].
BOROS, DL ;
WARREN, KS .
JOURNAL OF EXPERIMENTAL MEDICINE, 1970, 132 (03) :488-+
[5]   LEVAMISOLE RESTORED THE COMPROMIZED STATE OF IMMUNITY AFTER SPECIFIC CHEMOTHERAPY IN EXPERIMENTAL SCHISTOSOMIASIS-MANSONI [J].
BOTROS, SS ;
HASSAN, SI ;
ELNAHAL, HM ;
AZAB, ME ;
SHAKER, ZA ;
ELGAREM, A .
IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY, 1989, 11 (04) :611-629
[6]   STUDY OF SOME IMMUNOPHARMACOLOGICAL PROPERTIES OF PRAZIQUANTEL IN EXPERIMENTAL SCHISTOSOMIASIS-MANSONI [J].
BOTROS, SS ;
ELBADRAWY, N ;
METWALLY, AA ;
KHAYYAL, MT .
ANNALS OF TROPICAL MEDICINE AND PARASITOLOGY, 1986, 80 (02) :189-196
[7]  
BOTROS SS, 1996, INT J IMMUNOPHARMACO, V12, P707
[8]  
BOTROS SS, 1995, INT J IMMUNOPHAR, V1, P1
[9]  
BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
[10]  
CAPRON A, 1994, TROP GEOGR MED, V46, P242